Shattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average Price Target from Brokerages

Key Points

• Shattuck Labs, Inc. has an average rating of "Moderate Buy" from six analysts, with a target price of $4.00 over the next 12 months.
• The company's stock recently experienced a 2.6% increase and currently trades at $1.55 per share, showing a significant rise from its 52-week low of $0.69.
• Insider transactions included significant purchases by Orbimed Advisors and Director Mona Ashiya, acquiring over 6 million shares each at an average price of $0.87 per share.

Shattuck Labs, Inc. (NASDAQ:STTK - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, two have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.00.

A number of research analysts have weighed in on STTK shares. Wedbush started coverage on shares of Shattuck Labs in a research note on Monday, September 8th. They issued an "outperform" rating and a $4.00 price objective on the stock. Wall Street Zen raised shares of Shattuck Labs from a "sell" rating to a "hold" rating in a research report on Saturday. Leerink Partners dropped their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an "outperform" rating on the stock in a research report on Thursday, August 14th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Shattuck Labs in a research report on Thursday, August 14th.

Shattuck Labs Stock Down 3.0%

NASDAQ:STTK traded down $0.06 during trading hours on Monday, reaching $1.92. The company had a trading volume of 252,083 shares, compared to its average volume of 1,614,250. The firm has a market cap of $91.97 million, a price-to-earnings ratio of -1.59 and a beta of 1.64. The business's 50-day simple moving average is $1.00 and its two-hundred day simple moving average is $1.01. Shattuck Labs has a twelve month low of $0.69 and a twelve month high of $3.95.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.01. As a group, equities analysts predict that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Activity

In related news, Director Orbimed Advisors Llc acquired 6,306,127 shares of the stock in a transaction on Monday, August 25th. The shares were acquired at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the transaction, the director owned 5,255,106 shares in the company, valued at approximately $4,571,942.22. The trade was a -600.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mona Ashiya purchased 6,306,127 shares of the stock in a transaction dated Monday, August 25th. The stock was acquired at an average cost of $0.87 per share, for a total transaction of $5,486,330.49. Following the transaction, the director owned 5,255,106 shares of the company's stock, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.00% of the company's stock.

Hedge Funds Weigh In On Shattuck Labs

Hedge funds have recently bought and sold shares of the company. Prosight Management LP grew its stake in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company's stock worth $8,033,000 after buying an additional 873,409 shares in the last quarter. Jane Street Group LLC boosted its stake in shares of Shattuck Labs by 2,510.8% in the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company's stock valued at $229,000 after purchasing an additional 278,576 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Shattuck Labs during the 2nd quarter valued at $98,000. Bank of America Corp DE boosted its position in Shattuck Labs by 135.0% during the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company's stock valued at $226,000 after buying an additional 107,491 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in Shattuck Labs during the 1st quarter valued at $97,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.